Literature DB >> 14528081

Endocavitary radiation therapy for rectal adenocarcinoma: 10-year results.

Sophie Lavertu1, Steven E Schild, Leonard L Gunderson, Michael G Haddock, James A Martenson.   

Abstract

Local control, survival, and toxicity in patients treated with endocavitary radiation therapy for rectal cancer were evaluated. Thirty-five patients received a total of 20 to 155 Gy in 1 to 5 fractions with 50 kV x-rays through a treatment proctoscope. Twenty-nine of the 35 patients were treated with curative intent. Median follow-up was 102 months. Local control was achieved in 23 of the 29 patients treated curatively and in 3 of the 6 treated palliatively. Local control for patients treated curatively was 76% at 10 years. No local failures occurred after 21 months. For patients treated curatively, survival was 65% at 5 years and 42% at 10 years. Toxicity within 90 days after treatment was observed in 77% of the patients. Toxicity occurring more than 90 days after treatment was observed in 80%, but only 1 patient needed a colostomy, which was for a perforation after the biopsy of a benign ulcer. In conclusion, radiation therapy resulted in a local control rate of 76% at 10 years in curatively treated patients. Although most patients experience toxicity from this treatment, loss of sphincter function is rare.

Entities:  

Mesh:

Year:  2003        PMID: 14528081     DOI: 10.1097/01.coc.0000037763.66292.8C

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial.

Authors:  Shapour Omidvari; Shadi Zohourinia; Mansour Ansari; Leila Ghahramani; Mohammad Zare-Bandamiri; Ahmad Mosalaei; Niloofar Ahmadloo; Saeedeh Pourahmad; Hamid Nasrolahi; Sayed Hasan Hamedi; Mohammad Mohammadianpanah
Journal:  Ann Coloproctol       Date:  2015-08-31

Review 2.  Ablative therapies for colorectal polyps and malignancy.

Authors:  Jacqueline Oxenberg; Steven N Hochwald; Steven Nurkin
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.